day 28 remission
Minimal residual disease (MRD), measured at day 28 post treatment, is known to be prognostic. However there is no NGS based method that evaluate MRD using patient specific genetic markers. This study evaluates the feasibility of personalized NGS MRD method by studying error profiles of a variety of genetic alteration types including Indel and SV. We demonstrate superior performance of using Indel and SVs to measure MRD.